Literature DB >> 25584276

Prevalence of Heptavalent Vaccine-related Pneumococcal Serotypes in Nasopharyngeal carrier in children under five years old in Shahrekord, Iran by Multiplex-PCR during 2010- 2011.

Abolfazl Khoshdel1, Reza Imani Rastabi2, Abbas Doosti3, Shahin Askari4, Masoud Hafizi2.   

Abstract

BACKGROUND: Heptavalent pneumococcal vaccine which included pneumococcal serotypes 4, 6B, 9V,14, 18C, 19F and 23F has been regularly used and is effective on preventing invasive pneumococcal infection. This study aimed to determine vaccine-related serotype distribution in nasopharyngeal carrier and healthy children under five years old.
MATERIALS AND METHODS: In this cross-sectional study from September 2010 to September 2011, 363 nasopharyngeal specimens were collected from healthy children in day care centers. In positive cultures of streptococcus pneumoniae (S. pneumonia) distribution, serotypes were detected by Multiplex polymerase chain reaction (PCR). Electrophoresis of PCR products was used for detection of serotypes of S. pneumoniae.
RESULTS: The carrier rate of S. pneumoniae was 29.5% with 95% confidence interval as 24.8- 34.5%. Electrophoresis of PCR products for detection of serotypes of S. pneumonia revealed 430, 220, 753, 189, 573, 304, and 384 bp (s) for 4, 6B, 9V, 14, 18C, 19F, and 23F serotypes of S. pneumoniae, respectively. The frequency of 23F, 6B, 19F, and 18C serotypes were 43%, 34%, 18%, and 5% respectively, but other serotypes (4, 9V and 14) were not detected.
CONCLUSION: Based on the 30% carrier rate and high prevalence of most of heptavalent pneumococcal conjugate vaccine serotypes in our study, this vaccine should be used for prevention of invasive infection in Iranian children.

Entities:  

Keywords:  Electrophoresis; Heptavalent pneumococcal conjugate vaccine; PCR product; Streptococcus pneumoniae

Year:  2014        PMID: 25584276      PMCID: PMC4290297          DOI: 10.7860/JCDR/2014/8970.5104

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  26 in total

1.  Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.

Authors:  Mark van der Linden; Susanne Weiß; Gerhard Falkenhorst; Annette Siedler; Matthias Imöhl; Rüdiger von Kries
Journal:  Vaccine       Date:  2012-07-04       Impact factor: 3.641

Review 2.  Estimation of vaccine efficacy against acquisition of pneumococcal carriage.

Authors:  Hanna Rinta-Kokko; Ron Dagan; Noga Givon-Lavi; Kari Auranen
Journal:  Vaccine       Date:  2009-04-23       Impact factor: 3.641

3.  Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.

Authors:  Barbara E Mahon; Katherine Hsu; Sudharani Karumuri; Sheldon L Kaplan; Edward O Mason; Stephen I Pelton
Journal:  Vaccine       Date:  2005-12-27       Impact factor: 3.641

4.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

5.  Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups.

Authors:  Carrie L Byington; Matthew H Samore; Gregory J Stoddard; Steve Barlow; Judy Daly; Kent Korgenski; Sean Firth; David Glover; Jasmin Jensen; Edward O Mason; Cheryl K Shutt; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2005-05-26       Impact factor: 9.079

6.  American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.

Authors: 
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

Review 7.  Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project.

Authors:  Hope L Johnson; Maria Deloria-Knoll; Orin S Levine; Sonia K Stoszek; Laura Freimanis Hance; Richard Reithinger; Larry R Muenz; Katherine L O'Brien
Journal:  PLoS Med       Date:  2010-10-05       Impact factor: 11.069

8.  Multidrug resistance among different serotypes of clinical Salmonella isolates in Taiwan.

Authors:  Tsai-Ling Lauderdale; Frank M Aarestrup; Pei-Chen Chen; Jui-Fen Lai; Hui-Ying Wang; Yih-Ru Shiau; I-Wen Huang; Che-Lun Hung
Journal:  Diagn Microbiol Infect Dis       Date:  2006-03-09       Impact factor: 2.803

9.  Longitudinal study on pneumococcal carriage during the first year of life in Bangladesh.

Authors:  Simo M Granat; Zakaria Mia; Jukka Ollgren; Elja Herva; Milan Das; Liisa Piirainen; Kari Auranen; P Helena Mäkelä
Journal:  Pediatr Infect Dis J       Date:  2007-04       Impact factor: 2.129

10.  Nasopharyngeal Carriage, Antibiotic Resistance and Serotype Distribution of Streptococcus Pneumoniae among Healthy Adolescents in Zahedan.

Authors:  M Bokaeian; H A Khazaei; M Javadimehr
Journal:  Iran Red Crescent Med J       Date:  2011-05-01       Impact factor: 0.611

View more
  2 in total

1.  Pneumococcal serotype distribution: A snapshot of recent data in pediatric and adult populations around the world.

Authors:  Yadong A Cui; Harshila Patel; William M O'Neil; Se Li; Patricia Saddier
Journal:  Hum Vaccin Immunother       Date:  2017-01-26       Impact factor: 3.452

2.  Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?

Authors:  Chiara Azzari; Martina Cortimiglia; Francesco Nieddu; Maria Moriondo; Giuseppe Indolfi; Romano Mattei; Massimo Zuliani; Beatrice Adriani; Roberto Degl'Innocenti; Guglielmo Consales; Donatella Aquilini; Giancarlo Bini; Massimo Edoardo Di Natale; Clementina Canessa; Silvia Ricci; Elisa de Vitis; Giusi Mangone; Angela Bechini; Paolo Bonanni; Angela Pasinato; Massimo Resti
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.